Phase 2RecruitingPriority 2 · High priorityNCT05833724
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Plain-language summary
This Phase 2 trial is evaluating Chidamide as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 20 Years to 75 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Chidamide (DRUG): Subjects will receive a single dose of 30 mg chidamide. Twice a week.
- Drugs / treatments
- Chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details